NTRA Stock Forecast 2025-2026
Distance to NTRA Price Targets
NTRA Price Momentum
10 Quality Stocks Worth Considering Now
Researching Natera (NTRA) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on NTRA and similar high-potential opportunities.
Latest NTRA Stock Price Targets & Analyst Predictions
Based on our analysis of 25 Wall Street analysts, NTRA has a bullish consensus with a median price target of $195.00 (ranging from $37.00 to $251.00). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $148.08, the median forecast implies a 31.7% upside. This outlook is supported by 20 Buy, 0 Hold, and 1 Sell ratings.
The most optimistic forecast comes from Conor McNamara at RBC Capital, projecting a 69.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NTRA Analyst Ratings
NTRA Price Target Range
Latest NTRA Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NTRA.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 10, 2025 | Barclays | Luke Sergott | Overweight | Maintains | $160.00 |
| Mar 13, 2025 | RBC Capital | Conor McNamara | Outperform | Initiates | $251.00 |
| Mar 5, 2025 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $185.00 |
| Mar 4, 2025 | Piper Sandler | David Westenberg | Overweight | Maintains | $205.00 |
| Feb 28, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $195.00 |
| Feb 28, 2025 | Baird | Catherine Ramsey | Outperform | Maintains | $188.00 |
| Feb 26, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $180.00 |
| Jan 28, 2025 | Goldman Sachs | Matthew Sykes | Buy | Maintains | $190.00 |
| Jan 23, 2025 | Barclays | Luke Sergott | Overweight | Initiates | $200.00 |
| Jan 17, 2025 | Guggenheim | Subbu Nambi | Buy | Maintains | $200.00 |
| Jan 10, 2025 | Bernstein | Eve Burstein | Outperform | Maintains | $200.00 |
| Jan 3, 2025 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $180.00 |
| Dec 13, 2024 | JP Morgan | Julia Qin | Overweight | Maintains | $200.00 |
| Nov 18, 2024 | Piper Sandler | David Westenberg | Overweight | Maintains | $200.00 |
| Nov 14, 2024 | Morgan Stanley | Tejas Savant | Overweight | Maintains | $176.00 |
| Nov 13, 2024 | Craig-Hallum | Alexander Nowak | Buy | Maintains | $157.00 |
| Nov 13, 2024 | TD Cowen | Dan Brennan | Buy | Maintains | $175.00 |
| Nov 13, 2024 | JP Morgan | Julia Qin | Overweight | Maintains | $160.00 |
| Nov 13, 2024 | Baird | Catherine Ramsey | Outperform | Maintains | $160.00 |
| Nov 13, 2024 | Canaccord Genuity | Kyle Mikson | Buy | Maintains | $165.00 |
Natera Inc. (NTRA) Competitors
The following stocks are similar to Natera based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Natera Inc. (NTRA) Financial Data
Natera Inc. has a market capitalization of $20.02B with a P/E ratio of 0.0x. The company generates $1.70B in trailing twelve-month revenue with a -11.2% profit margin.
Revenue growth is +53.0% quarter-over-quarter, while maintaining an operating margin of -13.6% and return on equity of -19.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Natera Inc. (NTRA) Business Model
About Natera Inc.
Develops cell-free DNA testing technologies.
Natera Inc. generates revenue by offering a range of non-invasive genetic testing solutions focused on prenatal screening, oncology, and organ health. Its flagship product, Panorama, targets high-risk pregnancies, while its oncology solutions provide essential insights for early cancer detection and treatment guidance.
Based in San Carlos, California, Natera is a leader in the life sciences and diagnostics industry, leveraging innovative DNA analysis technologies to personalize medicine and improve patient care. The company's approach aims to enhance early diagnosis capabilities, which is crucial for better clinical outcomes.
Company Information
Sector
Healthcare
Industry
Diagnostics & Research
Employees
4,424
CEO
Mr. Steven Leonard Chapman
Country
United States
IPO Year
2015
Website
www.natera.comNatera Inc. (NTRA) Latest News & Analysis
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
2 days agoA breakthrough in oncology may benefit 18 million cancer survivors in the U.S. and positively impact companies such as Guardant Health, Natera, and Exact Sciences.
Advancements in oncology can enhance patient outcomes, potentially increasing market demand for companies like Guardant Health, Natera, and Exact Sciences, impacting their stock performance positively.
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks
13 days agoStanley Druckenmiller, a prominent investor, managed Duquesne Capital Management for 30 years, achieving an average annual return of 30%.
Stanley Druckenmiller's impressive track record and status among elite investors signal potential market insights, influencing investor sentiment and stock valuations.
Natera, Inc. (NASDAQ: NTRA) will present results from the DEFINE-HT study on donor-derived cell-free DNA in heart transplant recipients at the ISHLT Annual Meeting on April 29, 2025.
Natera's upcoming presentation on the DEFINE-HT study could impact its stock by influencing perceptions of its genetic testing technology's efficacy in heart transplantation, potentially driving investor interest.
Stanley Druckenmiller, a prominent hedge fund manager with a net worth of $6.9 billion, gained fame while working with George Soros until 2000.
Druckenmiller's status and experience signal confidence in investment strategies, potentially influencing market trends and investor sentiment. His moves could impact stock performance.
Natera Inc. demonstrates strong growth and high margins, supported by a solid genetic testing portfolio, with a recent pullback presenting a potential buying opportunity for investors.
Natera Inc. demonstrates solid growth and profitability, making it an appealing investment opportunity, especially after a recent price drop that enhances entry potential.
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
1 month agoNatera, Inc. (NASDAQ: NTRA) has enrolled the first patients in the HEROES phase II clinical trial, examining therapy de-escalation for metastatic HER2+ breast cancer, funded by the French Ministry of Health.
Natera's HEROES trial could lead to new treatment protocols for HER2+ breast cancer, potentially impacting market share and revenue from genetic testing and therapies.
Frequently Asked Questions About NTRA Stock
What is Natera Inc.'s (NTRA) stock forecast for 2025?
Based on our analysis of 25 Wall Street analysts, Natera Inc. (NTRA) has a median price target of $195.00. The highest price target is $251.00 and the lowest is $37.00.
Is NTRA stock a good investment in 2025?
According to current analyst ratings, NTRA has 20 Buy ratings, 0 Hold ratings, and 1 Sell ratings. The stock is currently trading at $148.08. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NTRA stock?
Wall Street analysts predict NTRA stock could reach $195.00 in the next 12 months. This represents a 31.7% increase from the current price of $148.08. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Natera Inc.'s business model?
Natera Inc. generates revenue by offering a range of non-invasive genetic testing solutions focused on prenatal screening, oncology, and organ health. Its flagship product, Panorama, targets high-risk pregnancies, while its oncology solutions provide essential insights for early cancer detection and treatment guidance.
What is the highest forecasted price for NTRA Natera Inc.?
The highest price target for NTRA is $251.00 from Conor McNamara at RBC Capital, which represents a 69.5% increase from the current price of $148.08.
What is the lowest forecasted price for NTRA Natera Inc.?
The lowest price target for NTRA is $37.00 from at , which represents a -75.0% decrease from the current price of $148.08.
What is the overall NTRA consensus from analysts for Natera Inc.?
The overall analyst consensus for NTRA is bullish. Out of 25 Wall Street analysts, 20 rate it as Buy, 0 as Hold, and 1 as Sell, with a median price target of $195.00.
How accurate are NTRA stock price projections?
Stock price projections, including those for Natera Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.